World Pharma News / Published News /

1
Vote

EMEA half-year report for 2008 shows activities to be on target

Posted by worldpharmanews 1 day 20 hours ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: emea

At its 60th meeting, held in London on 2 October 2008, the Management Board of the European Medicines Agency (EMEA) welcomed the half-year report for 2008 presented to them by EMEA Executive Director read more »
Discuss Add this link to... Bury

1
Vote

Genzyme Recognized by Scientists as a Top Employer

Posted by worldpharmanews 2 days ago (http://www.worldpharmanews.com)
Category: Corporate | Tags: genzyme

Genzyme Corporation (Nasdaq: GENZ) has announced that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. This ye read more »
Discuss Add this link to... Bury

3
Vote

Drug Injury Watch: Congress Will Investigate Digitek Recall And What FDA Knew About Actavis Manufacturing Problems

Posted by tjlpa 3 days ago (http://www.drug-injury.com)
Category: Blogs | Tags: digitek actavis fda drug-safety

After Earlier Class 1 Recall Of Digitek, All Acvtavis Drugs Manufactured At Its Little Falls, NJ Plant Were Recalled In August 2008 read more »
Discuss Add this link to... Bury

1
Vote

New Media Offers Cost-Efficient Ways to Reach and Engage Targets

Posted by worldpharmanews 3 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: manhattan research

Over 145 million U.S. adults use the Internet to research health information, according to pharmaceutical and healthcare market research company Manhattan Research. The company has just released Cybe read more »
Discuss Add this link to... Bury

1
Vote

Medicines regulators on both sides of the Atlantic confirm commitment to cooperation on medicines

Posted by worldpharmanews 3 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: ec emea fda

The European Commission (EC), the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) have affirmed their commitment to regulatory cooperation and to intensifyin read more »
Discuss Add this link to... Bury

2
Vote

Pharmacy Resources

Posted by santoshcotyson 4 days ago (http://pharmacy-myinterest.blogspot.com)
Category: Blogs | Tags: information pharmacy blog

This blog is a collection of several aspects of pharmacy like books, important pharmacy educational sites, articles, journals, etc. read more »
Discuss Add this link to... Bury

3
Vote

The One that Got Away: Lilly to Buy ImClone

Posted by cliffmz 4 days ago (http://www.biojobblog.com)
Category: Blogs | Tags: pharma biotech acquisition

After months of melodrama and acrimonious exchanges between Jim Cornelius and Carl Icahn, Eli Lilly, not Bristol-Myers Squibb, will acquire ImClone and gain access to the multibillion dollar Erbitux read more »
Discuss Add this link to... Bury

1
Vote

ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim

Posted by worldpharmanews 4 days ago (http://www.worldpharmanews.com)
Category: Research & Development | Tags: boehringer ingelheim award

The European Respiratory Society (ERS) has announced that Dr Esther Barreiro, Municipal Institute of Medical Investigation/Hospital del Mar in Barcelona, Spain is this year's winner of the Society' read more »
Discuss Add this link to... Bury

2
Vote

Novo Nordisk and Innate Pharma swap product rights

Posted by worldpharmanews 5 days ago (http://www.worldpharmanews.com)
Category: Financial | Tags: novo nordisk innate pharma

Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront paym read more »
Discuss Add this link to... Bury

1
Vote

Bayer Reports Progress in Clinical Program for Riociguat

Posted by worldpharmanews 6 days ago (http://www.worldpharmanews.com)
Category: Clinical Trials | Tags: bayer riociguat

Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilat read more »
Discuss Add this link to... Bury